CR20140480A - Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek - Google Patents
Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mekInfo
- Publication number
- CR20140480A CR20140480A CR20140480A CR20140480A CR20140480A CR 20140480 A CR20140480 A CR 20140480A CR 20140480 A CR20140480 A CR 20140480A CR 20140480 A CR20140480 A CR 20140480A CR 20140480 A CR20140480 A CR 20140480A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitor
- methods
- treat cancer
- mek
- pi3k
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan métodos de tratamiento de pacientes con cáncer, en donde los métodos comprenden administrar al paciente una cantidad eficaz de un inhibidor de MEK y una cantidad eficaz de un inhibidor de P13K.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261621252P | 2012-04-06 | 2012-04-06 | |
FR1351158 | 2013-02-12 | ||
US201361771457P | 2013-03-01 | 2013-03-01 | |
PCT/US2013/035231 WO2013152165A1 (en) | 2012-04-06 | 2013-04-04 | Methods for treating cancer using pi3k inhibitor and mek inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20140480A true CR20140480A (es) | 2014-11-17 |
Family
ID=49301040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20140480A CR20140480A (es) | 2012-04-06 | 2014-10-16 | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek |
Country Status (18)
Country | Link |
---|---|
US (1) | US20150031882A1 (es) |
EP (1) | EP2854854A1 (es) |
JP (1) | JP2015515476A (es) |
KR (1) | KR20150003786A (es) |
CN (1) | CN104334192A (es) |
AU (1) | AU2013243429A1 (es) |
CA (1) | CA2869152A1 (es) |
CL (1) | CL2014002668A1 (es) |
CO (1) | CO7121349A2 (es) |
CR (1) | CR20140480A (es) |
DO (1) | DOP2014000221A (es) |
EA (1) | EA201491836A1 (es) |
MX (1) | MX2014012001A (es) |
PE (1) | PE20142020A1 (es) |
PH (1) | PH12014502219A1 (es) |
SG (1) | SG11201406199TA (es) |
TN (1) | TN2014000418A1 (es) |
WO (1) | WO2013152165A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015095829A1 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |
WO2017065277A1 (ja) * | 2015-10-14 | 2017-04-20 | 日東紡績株式会社 | 2種のプロテインキナーゼの活性測定を用いる解析方法による、薬剤感受性ヒト細胞株の判定方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5214971B2 (ja) | 2004-10-20 | 2013-06-19 | メルク セローノ ソシエテ アノニム | 3−アリルアミノピペリジン誘導体 |
US8044062B2 (en) * | 2005-10-07 | 2011-10-25 | Exelixis, Inc. | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha |
BRPI0617162B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos |
JP2013507415A (ja) * | 2009-10-12 | 2013-03-04 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Pi3k阻害剤とmek阻害剤の併用 |
AR084216A1 (es) * | 2010-12-09 | 2013-05-02 | Sanofi Sa | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit |
-
2013
- 2013-04-04 AU AU2013243429A patent/AU2013243429A1/en not_active Abandoned
- 2013-04-04 WO PCT/US2013/035231 patent/WO2013152165A1/en active Application Filing
- 2013-04-04 EA EA201491836A patent/EA201491836A1/ru unknown
- 2013-04-04 CN CN201380029317.1A patent/CN104334192A/zh active Pending
- 2013-04-04 PE PE2014001533A patent/PE20142020A1/es not_active Application Discontinuation
- 2013-04-04 JP JP2015504716A patent/JP2015515476A/ja active Pending
- 2013-04-04 CA CA2869152A patent/CA2869152A1/en not_active Abandoned
- 2013-04-04 EP EP13717123.7A patent/EP2854854A1/en not_active Withdrawn
- 2013-04-04 KR KR20147030877A patent/KR20150003786A/ko not_active Application Discontinuation
- 2013-04-04 SG SG11201406199TA patent/SG11201406199TA/en unknown
- 2013-04-04 MX MX2014012001A patent/MX2014012001A/es unknown
-
2014
- 2014-10-01 PH PH12014502219A patent/PH12014502219A1/en unknown
- 2014-10-01 DO DO2014000221A patent/DOP2014000221A/es unknown
- 2014-10-02 TN TN2014000418A patent/TN2014000418A1/fr unknown
- 2014-10-02 US US14/504,970 patent/US20150031882A1/en not_active Abandoned
- 2014-10-03 CL CL2014002668A patent/CL2014002668A1/es unknown
- 2014-10-16 CR CR20140480A patent/CR20140480A/es unknown
- 2014-10-29 CO CO14239743A patent/CO7121349A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CL2014002668A1 (es) | 2015-01-16 |
TN2014000418A1 (en) | 2016-03-30 |
SG11201406199TA (en) | 2014-10-30 |
PH12014502219A1 (en) | 2015-01-12 |
CA2869152A1 (en) | 2013-10-10 |
JP2015515476A (ja) | 2015-05-28 |
MX2014012001A (es) | 2015-05-11 |
DOP2014000221A (es) | 2014-12-15 |
CN104334192A (zh) | 2015-02-04 |
EA201491836A1 (ru) | 2015-02-27 |
CO7121349A2 (es) | 2014-11-20 |
US20150031882A1 (en) | 2015-01-29 |
AU2013243429A1 (en) | 2014-10-23 |
WO2013152165A1 (en) | 2013-10-10 |
KR20150003786A (ko) | 2015-01-09 |
EP2854854A1 (en) | 2015-04-08 |
PE20142020A1 (es) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
NI201400095A (es) | Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa. | |
NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
CL2015002807A1 (es) | Terapia de combinación | |
NI201400109A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
CA2909625C (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
NI201500151A (es) | Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata. | |
NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
MX2015014344A (es) | Terapia contra el cancer. | |
NI201500063A (es) | Tratamiento de cáncer con pomalidomida en un individuo con daño renal | |
CR20140480A (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek | |
UY35033A (es) | Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa | |
NI201300052A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
CO6721062A2 (es) | Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek | |
ECSP13012736A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
GT201300148A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek | |
TN2013000247A1 (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer | |
EA201491695A1 (ru) | Лечение рака ингибиторами tor-киназы |